Monday, Bristol Myers Squibb & Co (NYSE:BMY) released data from the cohorts of the Phase 1/ 2 KRYSTAL-1 study evaluating Krazati (adagrasib) in combination with cetuximab for previously treated ...

The FDA has given accelerated approval to Krazati (adagrasib) as a combination with Eli Lilly’s anti-EGFR-antibody Erbitux (cetuximab) to treat patients with KRAS G12C-mutated, locally advanced ...

Among heavily pretreated patients with KRAS G12C-mutant unresectable or metastatic colorectal cancer (mCRC), the combination of Krazati (adagrasib) and Erbitux (cetuximab) has shown clinically ...

Bristol Myers BMY announced that the FDA has accepted its supplemental new drug application (sNDA) for Krazati (adagrasib) in combination with Erbitux (cetuximab) to treat patients with previously ...

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Quantum computing and artificial intelligence (AI) can be combined with classical computing methods to design and discover ...

Later this year, important next-wave data is expected for a CD19 NEX-T CAR-T program in autoimmune diseases; Krazati (adagrasib) in first-line non-small cell lung cancer; an EGFR x HER3 antibody ...